Using de-identified lab data to find patients, target physicians and expedite treatment

Pharmaceutical companies are increasingly integrating laboratory data into their core strategies because it offers real-time insights into patient diagnostics that lagging claims or electronic health records cannot provide. This immediacy allows pharma firms to engage physicians during the critical window when treatment decisions are being made, effectively shortening the time from diagnosis to prescription and ensuring patients receive timely care. By leveraging longitudinal lab results, companies can track disease progression and biomarker changes, enabling precise identification of ideal candidates for specific therapies. This data-driven approach transforms how pharma targets providers, allowing them to identify undiagnosed or at-risk populations and tailor outreach campaigns to address regional testing disparities or specific disease variants, thereby expanding patient access. This article is highly relevant to open data because it highlights the critical importance of integrating diverse, high-frequency data streams—specifically clinical lab results—with traditional real-world evidence. It demonstrates that opening up and linking granular, timely biological data with broader clinical and commercial datasets creates a more complete picture of the patient journey, which is essential for accurate analytics, effective drug development, and improving healthcare outcomes.

Source: biopharmadive.com
Published on 2024-10-10

Uno por uno, los diputados traidores a la universidad pública »

Open Data

Related news